A clinical study exploring the predictors of HPD after the use of nivolumab in advanced gastric cancer found that the frequencies of HPD in HER2-positive and negative gastric cancers are 23.4% (11/47) and 14.3% (2/14) (p = 0.71), respectively (22). Here, ERBB2 is linked to gastric cancer.